Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients/Experiment 1
From BugSigDB
Reviewed Marked as Reviewed by KateRasheed on 2025-6-13
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Cancer CA,cancer,cell type cancer,malignancy,malignant Growth,malignant neoplasm,malignant neoplasm (disease),malignant neoplastic disease,malignant tumor,MT,neoplasm (disease), malignant,neoplasm, malignant,organ system cancer,primary cancer,Cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cachectic Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- These are cancer patients who lost >5% body weight in the last 6 months.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 76
- Group 1 sample size Number of subjects in the case (exposed) group
- 33
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 Months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Wald Test
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-13
Source: Figure 2B& 3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachectic Cancer
| NCBI | Quality Control | Links |
|---|---|---|
| Pseudomonadota | ||
| Veillonella | ||
| unclassified Enterobacteriaceae |
Revision editor(s): Mautin
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-13
Source: Figure 2B &3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: decreased abundance in Cachectic Cancer
| NCBI | Quality Control | Links |
|---|---|---|
| Peptococcus |
Revision editor(s): Mautin
